Mangalam Drugs & Organics Limited (MANGALAM.BO)
INR 75.87
(4.16%)
INR 75.87
(4.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 27.45 Million INR | -81.81% |
| 2022 | 150.96 Million INR | -57.55% |
| 2021 | 355.66 Million INR | -19.76% |
| 2020 | 443.24 Million INR | 171.56% |
| 2019 | 163.22 Million INR | 485.91% |
| 2018 | 27.85 Million INR | -93.16% |
| 2017 | 407.28 Million INR | -3.36% |
| 2016 | 421.42 Million INR | 26.49% |
| 2015 | 333.16 Million INR | 156.2% |
| 2014 | 130.04 Million INR | 257.27% |
| 2013 | 36.39 Million INR | 153.71% |
| 2012 | -67.76 Million INR | -159.96% |
| 2011 | 113.02 Million INR | 14.59% |
| 2010 | 98.63 Million INR | 17.3% |
| 2009 | 84.08 Million INR | 18.2% |
| 2008 | 71.13 Million INR | 48.73% |
| 2007 | 47.83 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 43.12 Million INR | -44.93% |
| 2023 Q1 | -68.93 Million INR | -174.94% |
| 2023 FY | 27.45 Million INR | -81.81% |
| 2023 Q4 | 78.31 Million INR | 133.83% |
| 2023 Q3 | 33.49 Million INR | 314.25% |
| 2023 Q2 | -15.63 Million INR | 77.32% |
| 2022 Q3 | 35.85 Million INR | -3.55% |
| 2022 FY | 150.96 Million INR | -57.55% |
| 2022 Q4 | -25.07 Million INR | -169.92% |
| 2022 Q1 | 59.81 Million INR | -6.35% |
| 2022 Q2 | 37.17 Million INR | -37.84% |
| 2021 Q2 | 24.39 Million INR | -69.35% |
| 2021 Q4 | 63.87 Million INR | -45.13% |
| 2021 Q1 | 79.58 Million INR | 14.63% |
| 2021 Q3 | 116.4 Million INR | 377.16% |
| 2021 FY | 355.66 Million INR | -19.76% |
| 2020 Q1 | 122.11 Million INR | 683.52% |
| 2020 FY | 443.24 Million INR | 171.56% |
| 2020 Q3 | 115.37 Million INR | -28.07% |
| 2020 Q4 | 69.43 Million INR | -39.82% |
| 2020 Q2 | 160.39 Million INR | 31.35% |
| 2019 FY | 163.22 Million INR | 485.91% |
| 2019 Q1 | 36.94 Million INR | 211.63% |
| 2019 Q4 | 15.58 Million INR | -56.22% |
| 2019 Q2 | 38.85 Million INR | 5.18% |
| 2019 Q3 | 35.6 Million INR | -8.38% |
| 2018 FY | 27.85 Million INR | -93.16% |
| 2018 Q4 | -33.09 Million INR | -18.93% |
| 2018 Q3 | -27.82 Million INR | -173.78% |
| 2018 Q2 | 37.71 Million INR | 21.32% |
| 2018 Q1 | 31.08 Million INR | -55.82% |
| 2017 Q3 | 117.8 Million INR | -13.73% |
| 2017 Q2 | 136.54 Million INR | 57.74% |
| 2017 FY | 407.28 Million INR | -3.36% |
| 2017 Q1 | 86.56 Million INR | -30.63% |
| 2017 Q4 | 70.36 Million INR | -40.27% |
| 2016 Q2 | 94.83 Million INR | 11.21% |
| 2016 Q1 | 85.27 Million INR | -11.01% |
| 2016 Q4 | 124.78 Million INR | 15.86% |
| 2016 FY | 421.42 Million INR | 26.49% |
| 2016 Q3 | 107.7 Million INR | 13.58% |
| 2015 Q1 | 60.76 Million INR | 279.92% |
| 2015 Q2 | 93.52 Million INR | 53.91% |
| 2015 FY | 333.16 Million INR | 156.2% |
| 2015 Q4 | 95.81 Million INR | 23.51% |
| 2015 Q3 | 77.58 Million INR | -17.05% |
| 2014 Q2 | 48.92 Million INR | 94.86% |
| 2014 Q3 | 40.02 Million INR | -18.19% |
| 2014 FY | 130.04 Million INR | 257.27% |
| 2014 Q4 | 15.99 Million INR | -60.04% |
| 2014 Q1 | 25.1 Million INR | -50.76% |
| 2013 Q1 | -35.97 Million INR | -139.53% |
| 2013 Q2 | 15.32 Million INR | 142.6% |
| 2013 FY | 36.39 Million INR | 153.71% |
| 2013 Q4 | 50.98 Million INR | 81.9% |
| 2013 Q3 | 28.02 Million INR | 82.91% |
| 2012 Q1 | -36.57 Million INR | -493.92% |
| 2012 FY | -67.76 Million INR | -159.96% |
| 2012 Q4 | -15.01 Million INR | -904.34% |
| 2012 Q3 | 1.86 Million INR | 110.35% |
| 2012 Q2 | -18.03 Million INR | 50.68% |
| 2011 FY | 113.02 Million INR | 14.59% |
| 2011 Q4 | 9.28 Million INR | -68.52% |
| 2011 Q3 | 29.49 Million INR | 0.0% |
| 2010 FY | 98.63 Million INR | 17.3% |
| 2009 FY | 84.08 Million INR | 18.2% |
| 2008 FY | 71.13 Million INR | 48.73% |
| 2007 FY | 47.83 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 99.523% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.935% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 99.694% |
| Granules India Limited | 6.81 Billion INR | 99.597% |
| Indoco Remedies Limited | 1.29 Billion INR | 97.876% |
| Achyut Healthcare Limited | 4.43 Million INR | -518.702% |
| Ajanta Pharma Limited | 19.67 Billion INR | 99.86% |
| Alkem Laboratories Limited | 19.46 Billion INR | 99.859% |
| Alpa Laboratories Limited | 184.49 Million INR | 85.117% |
| Brooks Laboratories Limited | 14.44 Million INR | -90.152% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 98.401% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 97.769% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.959% |
| Eris Lifesciences Limited | 5.18 Billion INR | 99.47% |
| FDC Limited | 2.98 Billion INR | 99.081% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 99.578% |
| Gufic Biosciences Limited | 1.32 Billion INR | 97.935% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 99.379% |
| Ipca Laboratories Limited | 7.98 Billion INR | 99.656% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 94.596% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 118.07% |
| Lasa Supergenerics Limited | -458 Million INR | 105.995% |
| Laurus Labs Limited | 3.94 Billion INR | 99.305% |
| Lupin Limited | 28.04 Billion INR | 99.902% |
| Mankind Pharma Limited | 21.51 Billion INR | 99.872% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | 72.624% |
| Megasoft Limited | -121.1 Million INR | 122.673% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.894% |
| Piramal Pharma Limited | 4.55 Billion INR | 99.397% |
| RPG Life Sciences Limited | 2.29 Billion INR | 98.802% |
| Sigachi Industries Limited | 1.47 Billion INR | 98.137% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.974% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 99.404% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 88.984% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 95.18% |
| Windlas Biotech Limited | 1.29 Billion INR | 97.886% |
| ZIM Laboratories Limited | 253.82 Million INR | 89.182% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.936% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 100.667% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.917% |
| Hester Biosciences Limited | 364.81 Million INR | 92.473% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 99.014% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 93.999% |
| Bal Pharma Limited | 233.9 Million INR | 88.261% |
| Strides Pharma Science Limited | 5.22 Billion INR | 99.475% |
| Venus Remedies Limited | 534.65 Million INR | 94.864% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 99.122% |
| Nectar Lifesciences Limited | 923.8 Million INR | 97.028% |
| Shilpa Medicare Limited | 1.36 Billion INR | 97.99% |
| Aarti Drugs Limited | 7.14 Billion INR | 99.616% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 98.28% |
| Suven Life Sciences Limited | -1.22 Billion INR | 102.24% |
| Ind-Swift Limited | 1.22 Billion INR | 97.76% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 99.808% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 100.713% |
| Themis Medicare Limited | 392.58 Million INR | 93.006% |
| Hikal Limited | 32.11 Million INR | 14.488% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.892% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 95.617% |
| Wockhardt Limited | -670 Million INR | 104.098% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 99.471% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -202.778% |
| Neuland Laboratories Limited | 5.31 Billion INR | 99.484% |
| Morepen Laboratories Limited | 4.17 Billion INR | 99.342% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 86.802% |